^
Association details:
| Biomarker: | CLDN18.2 positive |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | AZD0901 (Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
Excerpt:
...- Part B: CLDN18.2-positive tumor sample assessed by central testing....
Trial ID:
Source:
Title:
A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors
Published date:
01/24/2023
Excerpt:
In CLDN18.2-positive gastric/GEJ cancer patients, ORR and DCR were 75.0% and 100%, respectively, with ORR of 100% in the 2.6, 3.0, and 3.4 mg/kg Q3W dose cohorts...CMG901 was well-tolerated with preliminary promising clinical efficacy in patients with CLDN18.2-positive gastric/GEJ cancer.
DOI:
10.1200/JCO.2023.41.4_suppl.352
Trial ID:
Source:
Title:
A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors.
Published date:
01/17/2023
Excerpt:
In CLDN18.2-positive gastric/GEJ cancer patients, ORR and DCR were 75.0% and 100%, respectively, with ORR of 100% in the 2.6, 3.0, and 3.4 mg/kg Q3W dose cohorts….CMG901 was well-tolerated with preliminary promising clinical efficacy in patients with CLDN18.2-positive gastric/GEJ cancer.
DOI:
10.1200/JCO.2023.41.3_suppl.352
Trial ID:
